leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 22:05:35 - browse：52

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Lack of health data on LGBTQ+ people has serious consequences

leisure time

WSS

Abridge raises $150m as clinical notes automation market heats up

Flagship Pioneering startup Sonata Therapeutics lays off 21

Abridge raises $150m as clinical notes automation market heats up

The public health thinking behind the CDC’s new Covid guidance

Stem cell biologist probes earliest stages of human development

Microsoft's Peter Lee: Generative AI could help doctors be more human

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Walensky prepares to leave CDC — and Congress — behind

Abridge raises $150m as clinical notes automation market heats up

Heart attack and stroke risk calculators need revising

Stem cell biologist probes earliest stages of human development

Apple is now the first public company to be valued at $3 trillion

Change Healthcare: What is it, why does its cyberattack matter?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hospitals are piloting generative AI tools as regulators play catch

Peter Hotez and the public health issue of online harassment

The public health thinking behind the CDC’s new Covid guidance

hotspot

Why Talkspace is targeting Medicare, a tricky market

For AI in health care standards, federal regulators join with industry group

IVF doctors demand details after CooperSurgical lawsuit

Ozempic has benefits for kidney disease as well as diabetes

Abridge raises $150m as clinical notes automation market heats up

Ozempic has benefits for kidney disease as well as diabetes

leisure time

knowledge

entertainment

Wikipedia